The New Combination 2 (NC-002) trial continued to develop the PaMZ TB treatment regimen. The PaMZ regimen is comprised of new TB drug candidates PA-824 and moxifloxacin, along with the existing TB drug, pyrazinamide. The Phase 2, 8-week trial was the first of its kind, as it will enroll both drug-sensitive TB (DS-TB) and multidrug-resistant (MDR-TB) patients and treat them with the same regimen. If successful, NC-002 will pave the way for Phase 3 registration studies of the PaMZ regimen. NC-002 was launched in 2012 and completed in 2013.
NC002 Phase II Trial to Evaluate the Efficacy, Safety and Tolerability of the Following: PA-824 Plus Moxifloxacin Plus Pyrazinamide in Drug Sensitive and Multi-Drug Resistant Patients